(Q42252882)

19 October 2017

title

Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms (English)

1 reference

19 October 2017

Dag Kvale

9

0 references

Andreas Lind

object named as

Andreas Lind

1

0 references

author name string

Kristin Brekke

2

1 reference

19 October 2017

Maja Sommerfelt

3

1 reference

19 October 2017

Jens O Holmberg

4

1 reference

19 October 2017

Hans Christian D Aass

5

1 reference

19 October 2017

Ingebjørg Baksaas

6

1 reference

19 October 2017

Birger Sørensen

7

1 reference

19 October 2017

Anne Ma Dyrhol-Riise

8

1 reference

19 October 2017

language of work or name

English

0 references

publication date

30 July 2013

1 reference

19 October 2017

1 reference

19 October 2017

volume

31

1 reference

19 October 2017

issue

41

1 reference

19 October 2017

page(s)

4611-4618

1 reference

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Protective HIV-specific CD8+ T cells evade Treg cell suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Homeostasis and function of regulatory T cells in HIV/SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Hepatitis C Virus (HCV)-Specific CD8+ Cells Produce Transforming Growth Factor That Can Suppress HCV-Specific T-Cell Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Flow cytometry controls, instrument setup, and the determination of positivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.037

10.1016/J.VACCINE.2013.07.037

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference